Date:2/27/2009

care cost containment; and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K, particularly the discussion under the caption "Item 1A, RISK FACTORS" in our annual report on Form 10-K/A for the year ended December 31, 2007, which was filed with the Securities and Exchange Commission on April 29, 2008. The forward-looking statements in this press release and on the related conference call are qualified by these risk factors. These are factors that, individually or in the aggregate, we think could cause our actual results to differ materially from expected and historical results. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

'/>"/>

SOURCE Endo Pharmaceuticals Copyright©2009 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4
Related medicine news :

1. AstraZeneca Licenses Novel Antidepressant Compounds Discovered by Mayo Clinic and Virginia Tech Collaboration
2. Most inactive physicians retain licenses, return to practice without competency review
3. Global Med Technologies(R) Licenses Multi-System Solution to One of Top Ten U.S. Donor Centers
4. Enigma Diagnostics Announces a Signed Term Sheet for Patent Licenses with Roche Molecular Systems, Inc.
5. Global Med Technologies(R), Inc.s Inlog Subsidiary Licenses Its Leading Laboratory Information System to Gabriel Martin Hospital of Saint-Paul de la Reunion
6. Perrigo Company Licenses Prescription Brands to Medimetriks Pharmaceuticals
7. ChromaDex Licenses Green Chemistry Technology to Manufacture a New Class of Super Fruit Compounds
8. Vital Images Europe Surpasses 1,000 Licenses
9. US FDA licenses Sanofi Pasteurs new pediatric combination vaccine, pentacel
10. U.S. FDA Licenses Sanofi Pasteurs New Pediatric Combination Vaccine, Pentacel(R)
11. MonoSol Rx Licenses Thin Film Formulation of Ondansetron to Strativa Pharmaceuticals, a Division of Par Pharmaceutical